Posted by Michael Wonder on 29 Apr 2020
FDA grants Carmell Therapeutics expedited review for CT-101, bone healing accelerant
27 April 2020 - Carmell to begin enrolling in pivotal clinical program for first-of-its-kind plasma-based bioactive material product used in long-bone fractures as an adjunctive treatment.
Carmell Therapeutics announced that the U.S. FDA last week has granted fast track designation for the Company’s first product, a bone healing accelerant.
